ClinicalTrials.gg
CompletedNCT03512288Updated Mar 2, 2021Results posted

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

A Phase 2 interventional study of Multivalent and 13vPnC in Pneumococcal Infections, sponsored by Pfizer. Completed at 39 sites in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.

Enrollment
34th of 57
460 · median 570
Started
2018
with 5 others
Phase 2
7 of 75
none open now
Registered
41st of 75
by date

Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 34th largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2018, is one of 7 in phase 2, and was the 41st registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 98 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Pneumococcal Infections by Pfizer, or all of them as a file.
02

Study summary

A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants

Read the detailed description

NOTE: Detailed description has not been entered.

03

Conditions studied

  • Pneumococcal Infections
04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female infant born at >36 weeks of gestation and aged 2 months (42 to 98 days) at the time of consent (the day of birth is considered day of life 1).
  • Healthy infant determined by medical history, physical examination, and clinical judgment to be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with licensed or pneumococcal vaccine.
  • Prior receipt of diphtheria, tetanus, pertussis, or polio vaccines.
  • Previous receipt of >1 dose of vaccine.
  • Prior hepatitis B vaccine must have been administered at age \<30 days.
  • Major known congenital malformation or serious chronic disorder. Receipt of blood/plasma products or immunoglobulins
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    Multivalent

    Pneumococcal conjugate vaccines

    Biological: Multivalent

  • Active comparator
    Control

    13vPnC

    Biological: 13vPnC

Interventions

  • BiologicalMultivalent

    Pneumococcal conjugate vaccine

    Also known as: Pneumococcal conjugate vaccine

  • Biological13vPnC

    Pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

    Time frame: Within 7 days after Vaccination 1

  2. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

    Time frame: Within 7 days after Vaccination 2

  3. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

    Time frame: Within 7 days after Vaccination 3

  4. Percentage of Participants With Local Reactions Within 7 Days After Vaccination 4

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

    Time frame: Within 7 days after Vaccination 4

  5. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

    Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

    Time frame: Within 7 days after Vaccination 1

  6. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

    Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

    Time frame: Within 7 days after Vaccination 2

  7. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3

    Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

    Time frame: Within 7 days after Vaccination 3

  8. Percentage of Participants With Systemic Events Within 7 Days After Vaccination 4

    Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

    Time frame: Within 7 days after Vaccination 4

  9. Percentage of Participants With Adverse Events (AEs) From Vaccination 1 to 1 Month After Vaccination 3

    An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship.

    Time frame: From Vaccination 1 to 1 month after Vaccination 3 (up to 5 months)

  10. Percentage of Participants With Adverse Events (AEs) From Vaccination 4 to 1 Month After Vaccination 4

    An AE was any untoward medical occurrence in study participant who received study vaccine without regard to possibility of causal relationship.

    Time frame: From Vaccination 4 to 1 month after Vaccination 4

  11. Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 to 6 Months Following Vaccination 4

    An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.

    Time frame: From Vaccination 1 to 6 months after Vaccination 4 (up to 16 months)

  12. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination 1 to 6 Months Following Vaccination 4

    An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or is otherwise long-lasting in its effects.

    Time frame: From Vaccination 1 to 6 months after Vaccination 4 (duration of 16 months)

Secondary outcomes

  1. Percentage of Participants Who Achieved Pre-specified Level of Pneumococcal IgG Concentrations Within 1 Month After Vaccination 3

    Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per milliliter, for serotype 5: \>=0.23 microgram per milliliter, for serotype 6B: \>=0.10 microgram per milliliter and for serotype 19A: \>=0.12 microgram per milliliter.

    Time frame: 1 month after Vaccination 3

  2. Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination 3

    IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: 1 month after Vaccination 3

  3. Pneumococcal Serotype-specific IgG GMCs at 1 Month After Vaccination 4

    IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

    Time frame: 1 Month after Vaccination 4

07

Results

Posted Mar 2, 2021

Participant flow

Participants were enrolled from 16 April 2018 to 11 February 2020 in the United States.

Participant flow — Overall Study
Milestone20vPnC13vPnC
Started232228
Vaccination 1231227
Vaccination 2222213
Vaccination 3210206
Vaccination 4197194
Completed191185
Not completed4143
Withdrew: Adverse event10
Withdrew: Lost to follow-up1215
Withdrew: Physician decision02
Withdrew: Protocol violation64
Withdrew: Medication error without associated adverse event10
Withdrew: No longer met eligibility criteria52
Withdrew: Withdrawal by parent/guardian1418
Withdrew: Other11
Withdrew: Randomized but not treated11

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 1

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

Time frame:
Within 7 days after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
percentage of participants20vPnC13vPnC
Redness: Any24.9 (19.4 to 31.0)25.4 (19.9 to 31.7)
Redness: Mild22.3 (17.1 to 28.2)23.7 (18.3 to 29.8)
Redness: Moderate2.6 (1.0 to 5.6)1.8 (0.5 to 4.5)
Redness: Severe0 (0.0 to 1.6)0 (0.0 to 1.6)
Swelling: Any12.7 (8.6 to 17.7)14.3 (10.0 to 19.6)
Swelling: Mild10.0 (6.5 to 14.7)12.9 (8.8 to 18.1)
Swelling: Moderate2.2 (0.7 to 5.0)1.3 (0.3 to 3.9)
Swelling: Severe0.4 (0.0 to 2.4)0 (0.0 to 1.6)
Pain at the injection site: Any51.1 (44.4 to 57.7)53.6 (46.8 to 60.2)
Pain at the injection site: Mild32.3 (26.3 to 38.8)35.7 (29.4 to 42.4)
Pain at the injection site: Moderate18.3 (13.5 to 24.0)17.9 (13.1 to 23.5)
Pain at the injection site: Severe0.4 (0.0 to 2.4)0 (0.0 to 1.6)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 2

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

Time frame:
Within 7 days after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
percentage of participants20vPnC13vPnC
Redness: Any24.7 (19.0 to 31.0)28.4 (22.4 to 35.2)
Redness: Mild21.9 (16.5 to 28.0)24.0 (18.3 to 30.5)
Redness: Moderate2.8 (1.0 to 6.0)4.4 (2.0 to 8.20)
Redness: Severe0 (0.0 to 1.7)0 (0.0 to 1.8)
Swelling: Any16.3 (11.6 to 21.9)18.6 (13.5 to 24.7)
Swelling: Mild12.6 (8.4 to 17.7)13.2 (8.9 to 18.7)
Swelling: Moderate3.7 (1.6 to 7.2)5.4 (2.7 to 9.4)
Swelling: Severe0 (0.0 to 1.7)0 (0.0 to 1.8)
Pain at the injection site: Any42.8 (36.1 to 49.7)48.5 (41.5 to 55.6)
Pain at the injection site: Mild26.0 (20.3 to 32.5)28.9 (22.8 to 35.7)
Pain at the injection site: Moderate15.8 (11.2 to 21.4)19.6 (14.4 to 25.7)
Pain at the injection site: Severe0.9 (0.1 to 3.3)0 (0.0 to 1.8)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 3

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

Time frame:
Within 7 days after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3
percentage of participants20vPnC13vPnC
Redness: Any26.9 (20.9 to 33.6)26.5 (20.6 to 33.1)
Redness: Mild26.4 (20.4 to 33.0)23.0 (17.4 to 29.4)
Redness: Moderate0.5 (0.0 to 2.7)3.4 (1.4 to 6.9)
Redness: Severe0 (0.0 to 1.8)0 (0.0 to 1.8)
Swelling: Any17.9 (12.9 to 23.9)19.6 (14.4 to 25.7)
Swelling: Mild16.9 (12.0 to 22.8)15.7 (11.0 to 21.4)
Swelling: Moderate1.0 (0.1 to 3.5)3.4 (1.4 to 6.9)
Swelling: Severe0 (0.0 to 1.8)0.5 (0.0 to 2.7)
Pain at the injection site: Any44.3 (37.3 to 51.4)40.7 (33.9 to 47.8)
Pain at the injection site: Mild28.9 (22.7 to 35.6)27.9 (21.9 to 34.6)
Pain at the injection site: Moderate14.9 (10.3 to 20.6)12.7 (8.5 to 18.1)
Pain at the injection site: Severe0.5 (0.0 to 2.7)0 (0.0 to 1.8)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination 4

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

Time frame:
Within 7 days after Vaccination 4
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 4
percentage of participants20vPnC13vPnC
Redness: Any25.8 (19.7 to 32.7)30.3 (23.7 to 37.4)
Redness: Mild24.2 (18.2 to 31.0)25.4 (19.3 to 32.3)
Redness: Moderate1.6 (0.3 to 4.6)4.9 (2.2 to 9.0)
Redness: Severe0 (0.0 to 2.0)0 (0.0 to 2.0)
Swelling: Any17.2 (12.1 to 23.4)14.1 (9.4 to 19.9)
Swelling: Mild15.1 (10.2 to 21.0)12.4 (8.0 to 18.1)
Swelling: Moderate2.2 (0.6 to 5.4)1.6 (0.3 to 4.7)
Swelling: Severe0 (0.0 to 2.0)0 (0.0 to 2.0)
Pain at the injection site: Any35.5 (28.6 to 42.8)35.7 (28.8 to 43.0)
Pain at the injection site: Mild26.9 (20.7 to 33.9)28.6 (22.3 to 35.7)
Pain at the injection site: Moderate8.6 (5.0 to 13.6)7.0 (3.8 to 11.7)
Pain at the injection site: Severe0 (0.0 to 2.0)0 (0.0 to 2.0)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 1

Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

Time frame:
Within 7 days after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
percentage of participants20vPnC13vPnC
Fever: >=38.0 degree C14.4 (10.1 to 19.6)9.8 (6.3 to 14.5)
Fever: >=38.0 degree C to 38.4 degree C10.0 (6.5 to 14.7)6.3 (3.5 to 10.3)
Fever: >38.4 degree C to 38.9 degree C3.9 (1.8 to 7.3)2.2 (0.7 to 5.1)
Fever: >38.9 degree C to 40.0 degree C0.4 (0.0 to 2.4)1.3 (0.3 to 3.9)
Fever: >40.0 degree C0 (0.0 to 1.6)0 (0.0 to 1.6)
Decreased appetite: Any25.3 (19.8 to 31.5)30.4 (24.4 to 36.8)
Decreased appetite: Mild16.2 (11.6 to 21.6)19.2 (14.3 to 25.0)
Decreased appetite: Moderate9.2 (5.8 to 13.7)10.7 (7.0 to 15.5)
Decreased appetite: Severe0 (0.0 to 1.6)0.4 (0.0 to 2.5)
Drowsiness: Any68.1 (61.7 to 74.1)71.0 (64.6 to 76.8)
Drowsiness: Mild51.1 (44.4 to 57.7)54.9 (48.1 to 61.5)
Drowsiness: Moderate16.6 (12.0 to 22.1)14.3 (10.0 to 19.6)
Drowsiness: Severe0.4 (0.0 to 2.4)1.8 (0.5 to 4.5)
Irritability: Any79.5 (73.7 to 84.5)77.7 (71.7 to 83.0)
Irritability: Mild23.6 (18.2 to 29.6)25.9 (20.3 to 32.1)
Irritability: Moderate50.7 (44.0 to 57.3)47.3 (40.6 to 54.1)
Irritability: Severe5.2 (2.7 to 9.0)4.5 (2.2 to 8.1)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 2

Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

Time frame:
Within 7 days after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
percentage of participants20vPnC13vPnC
Fever: >=38.0 degree C17.2 (12.4 to 22.9)23.0 (17.4 to 29.4)
Fever: >=38.0 degree C to 38.4 degree C10.2 (6.5 to 15.1)12.7 (8.5 to 18.1)
Fever: >38.4 degree C to 38.9 degree C4.2 (1.9 to 7.8)7.8 (4.5 to 12.4)
Fever: >38.9 degree C to 40.0 degree C2.8 (1.0 to 6.0)2.5 (0.8 to 5.6)
Fever: >40.0 degree C0 (0.0 to 1.7)0 (0.0 to 1.8)
Decreased appetite: Any23.3 (17.8 to 29.5)27.0 (21.0 to 33.6)
Decreased appetite: Mild14.4 (10.0 to 19.8)14.7 (10.1 to 20.3)
Decreased appetite: Moderate7.9 (4.7 to 12.4)11.8 (7.7 to 17.0)
Decreased appetite: Severe0.9 (0.1 to 3.3)0.5 (0.0 to 2.7)
Drowsiness: Any57.2 (50.3 to 63.9)56.4 (49.3 to 63.3)
Drowsiness: Mild37.2 (30.7 to 44.0)37.7 (31.1 to 44.8)
Drowsiness: Moderate17.7 (12.8 to 23.4)16.7 (11.8 to 22.5)
Drowsiness: Severe2.3 (0.8 to 5.3)2.0 (0.5 to 4.9)
Irritability: Any71.2 (64.6 to 77.1)79.9 (73.7 to 85.2)
Irritability: Mild20.0 (14.9 to 26.0)22.5 (17.0 to 28.9)
Irritability: Moderate48.8 (42.0 to 55.7)52.5 (45.4 to 59.5)
Irritability: Severe2.3 (0.8 to 5.3)4.9 (2.4 to 8.8)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 3

Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

Time frame:
Within 7 days after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3
percentage of participants20vPnC13vPnC
Fever: >=38.0 degree C17.9 (12.9 to 23.9)18.1 (13.1 to 24.1)
Fever: >=38.0 degree C to 38.4 degree C10.0 (6.2 to 14.9)9.8 (6.1 to 14.7)
Fever: >38.4 degree C to 38.9 degree C4.5 (2.1 to 8.3)4.9 (2.4 to 8.8)
Fever: >38.9 degree C to 40.0 degree C3.5 (1.4 to 7.0)3.4 (1.4 to 6.9)
Fever: >40.0 degree C0 (0.0 to 1.8)0 (0.0 to 1.8)
Decreased appetite: Any30.8 (24.5 to 37.7)33.3 (26.9 to 40.3)
Decreased appetite: Mild20.9 (15.5 to 27.2)19.1 (14.0 to 25.2)
Decreased appetite: Moderate9.5 (5.8 to 14.4)13.7 (9.3 to 19.2)
Decreased appetite: Severe0.5 (0.0 to 2.7)0.5 (0.0 to 2.7)
Drowsiness: Any41.3 (34.4 to 48.4)45.6 (38.6 to 52.7)
Drowsiness: Mild28.9 (22.7 to 35.6)29.9 (23.7 to 36.7)
Drowsiness: Moderate11.4 (7.4 to 16.7)15.7 (11.0 to 21.4)
Drowsiness: Severe1.0 (0.1 to 3.5)0 (0.0 to 1.8)
Irritability: Any72.6 (65.9 to 78.7)69.6 (62.8 to 75.8)
Irritability: Mild28.9 (22.7 to 35.6)27.5 (21.5 to 34.1)
Irritability: Moderate40.8 (33.9 to 47.9)37.7 (31.1 to 44.8)
Irritability: Severe3.0 (1.1 to 6.4)4.4 (2.0 to 8.2)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination 4

Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).

Time frame:
Within 7 days after Vaccination 4
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 4
percentage of participants20vPnC13vPnC
Fever: >=38.0 degree C12.4 (8.0 to 18.0)14.6 (9.8 to 20.5)
Fever: >=38.0 degree C to 38.4 degree C5.9 (3.0 to 10.3)4.3 (1.9 to 8.3)
Fever: >38.4 degree C to 38.9 degree C3.2 (1.2 to 6.9)7.0 (3.8 to 11.7)
Fever: >38.9 degree C to 40.0 degree C3.2 (1.2 to 6.9)3.2 (1.2 to 6.9)
Fever: >40.0 degree C0 (0.0 to 2.0)0 (0.0 to 2.0)
Decreased appetite: Any23.7 (17.7 to 30.4)29.2 (22.8 to 36.3)
Decreased appetite: Mild13.4 (8.9 to 19.2)15.7 (10.8 to 21.7)
Decreased appetite: Moderate10.2 (6.3 to 15.5)13.5 (8.9 to 19.3)
Decreased appetite: Severe0 (0.0 to 2.0)0 (0.0 to 2.0)
Drowsiness: Any32.8 (26.1 to 40.0)37.3 (30.3 to 44.7)
Drowsiness: Mild26.9 (20.7 to 33.9)25.4 (19.3 to 32.3)
Drowsiness: Moderate4.8 (2.2 to 9.0)11.9 (7.6 to 17.4)
Drowsiness: Severe1.1 (0.1 to 3.8)0 (0.0 to 2.0)
Irritability: Any62.4 (55.0 to 69.3)62.7 (55.3 to 69.7)
Irritability: Mild23.7 (17.7 to 30.4)19.5 (14.0 to 25.9)
Irritability: Moderate36.0 (29.1 to 43.4)40.0 (32.9 to 47.4)
Irritability: Severe2.7 (0.9 to 6.2)3.2 (1.2 to 6.9)
PrimaryPercentage of Participants With Adverse Events (AEs) From Vaccination 1 to 1 Month After Vaccination 3

An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship.

Time frame:
From Vaccination 1 to 1 month after Vaccination 3 (up to 5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) From Vaccination 1 to 1 Month After Vaccination 3
percentage of participants20vPnC13vPnC
Percentage of Participants With Adverse Events (AEs) From Vaccination 1 to 1 Month After Vaccination 361.0 (54.4 to 67.4)56.4 (49.7 to 62.9)
PrimaryPercentage of Participants With Adverse Events (AEs) From Vaccination 4 to 1 Month After Vaccination 4

An AE was any untoward medical occurrence in study participant who received study vaccine without regard to possibility of causal relationship.

Time frame:
From Vaccination 4 to 1 month after Vaccination 4
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) From Vaccination 4 to 1 Month After Vaccination 4
percentage of participants20vPnC13vPnC
Percentage of Participants With Adverse Events (AEs) From Vaccination 4 to 1 Month After Vaccination 418.3 (13.1 to 24.4)25.3 (19.3 to 32.0)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 to 6 Months Following Vaccination 4

An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.

Time frame:
From Vaccination 1 to 6 months after Vaccination 4 (up to 16 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 to 6 Months Following Vaccination 4
percentage of participants20vPnC13vPnC
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 to 6 Months Following Vaccination 45.2 (2.7 to 8.9)2.2 (0.7 to 5.1)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination 1 to 6 Months Following Vaccination 4

An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or is otherwise long-lasting in its effects.

Time frame:
From Vaccination 1 to 6 months after Vaccination 4 (duration of 16 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination 1 to 6 Months Following Vaccination 4
percentage of participants20vPnC13vPnC
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination 1 to 6 Months Following Vaccination 45.2 (2.7 to 8.9)3.5 (1.5 to 6.8)
SecondaryPercentage of Participants Who Achieved Pre-specified Level of Pneumococcal IgG Concentrations Within 1 Month After Vaccination 3

Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per milliliter, for serotype 5: \>=0.23 microgram per milliliter, for serotype 6B: \>=0.10 microgram per milliliter and for serotype 19A: \>=0.12 microgram per milliliter.

Time frame:
1 month after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Pre-specified Level of Pneumococcal IgG Concentrations Within 1 Month After Vaccination 3
percentage of participants20vPnC13vPnC
Serotype 187.8 (82.3 to 92.1)87.7 (82.1 to 92.0)
Serotype 365.1 (57.8 to 71.9)75.4 (68.6 to 81.4)
Serotype 487.8 (82.3 to 92.1)91.4 (86.5 to 95.0)
Serotype 587.8 (82.3 to 92.1)89.8 (84.6 to 93.8)
Serotype 6A93.7 (89.2 to 96.7)92.5 (87.8 to 95.8)
Serotype 6B86.8 (81.1 to 91.3)90.4 (85.2 to 94.2)
Serotype 7F98.9 (96.2 to 99.9)97.9 (94.6 to 99.4)
Serotype 9V89.4 (84.1 to 93.4)89.3 (84.0 to 93.3)
Serotype 1494.2 (89.8 to 97.1)95.7 (91.7 to 98.1)
Serotype 18C92.6 (87.9 to 95.9)95.2 (91.1 to 97.8)
Serotype 19A98.4 (95.4 to 99.7)97.9 (94.6 to 99.4)
Serotype 19F98.4 (95.4 to 99.7)96.8 (93.1 to 98.8)
Serotype 23F79.9 (73.5 to 85.4)81.8 (75.5 to 87.1)
Serotype 899.5 (97.1 to 100.0)3.7 (1.5 to 7.6)
Serotype 10A87.8 (82.3 to 92.1)1.1 (0.1 to 3.8)
Serotype 11A97.4 (93.9 to 99.1)1.6 (0.3 to 4.6)
Serotype 12F82.5 (76.4 to 87.7)0.5 (0.0 to 2.9)
Serotype 15B98.9 (96.2 to 99.9)4.3 (1.9 to 8.3)
Serotype 22F98.9 (96.2 to 99.9)1.1 (0.1 to 3.8)
Serotype 33F92.1 (87.2 to 95.5)1.6 (0.3 to 4.6)
SecondaryPneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination 3

IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
1 month after Vaccination 3
Reported as:
Geometric mean · microgram per milliliter
Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination 3
microgram per milliliter20vPnC13vPnC
Serotype 10.92 (0.81 to 1.05)1.16 (1.00 to 1.33)
Serotype 30.43 (0.38 to 0.48)0.56 (0.49 to 0.64)
Serotype 41.36 (1.16 to 1.61)1.64 (1.39 to 1.93)
Serotype 50.93 (0.79 to 1.11)1.13 (0.96 to 1.34)
Serotype 6A2.28 (1.94 to 2.67)2.57 (2.16 to 3.05)
Serotype 6B0.63 (0.49 to 0.80)0.99 (0.77 to 1.27)
Serotype 7F2.15 (1.92 to 2.40)2.59 (2.28 to 2.93)
Serotype 9V1.22 (1.05 to 1.42)1.45 (1.24 to 1.70)
Serotype 143.15 (2.69 to 3.70)3.60 (3.07 to 4.21)
Serotype 18C1.59 (1.37 to 1.84)2.05 (1.76 to 2.38)
Serotype 19A0.85 (0.74 to 0.96)1.02 (0.89 to 1.17)
Serotype 19F1.98 (1.76 to 2.22)2.28 (1.99 to 2.61)
Serotype 23F0.94 (0.78 to 1.14)1.26 (1.03 to 1.55)
Serotype 82.09 (1.90 to 2.30)0.04 (0.03 to 0.04)
Serotype 10A1.67 (1.35 to 2.08)0.03 (0.03 to 0.03)
Serotype 11A1.94 (1.70 to 2.21)0.01 (0.01 to 0.01)
Serotype 12F0.86 (0.72 to 1.01)0.02 (0.02 to 0.02)
Serotype 15B5.86 (5.11 to 6.72)0.04 (0.04 to 0.05)
Serotype 22F4.62 (3.99 to 5.35)0.01 (0.01 to 0.01)
Serotype 33F2.21 (1.87 to 2.61)0.05 (0.04 to 0.05)
SecondaryPneumococcal Serotype-specific IgG GMCs at 1 Month After Vaccination 4

IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.

Time frame:
1 Month after Vaccination 4
Reported as:
Geometric mean · microgram per milliliter
Pneumococcal Serotype-specific IgG GMCs at 1 Month After Vaccination 4
microgram per milliliter20vPnC13vPnC
Serotype 12.65 (2.33 to 3.02)3.63 (3.20 to 4.11)
Serotype 31.15 (0.97 to 1.35)1.49 (1.28 to 1.74)
Serotype 47.16 (6.22 to 8.24)9.45 (8.16 to 10.95)
Serotype 53.41 (2.95 to 3.93)4.95 (4.29 to 5.71)
Serotype 6A13.77 (12.16 to 15.59)18.83 (16.39 to 21.63)
Serotype 6B6.37 (5.42 to 7.50)9.73 (8.13 to 11.65)
Serotype 7F6.14 (5.51 to 6.83)9.32 (8.26 to 10.52)
Serotype 9V5.52 (4.82 to 6.31)7.78 (6.77 to 8.95)
Serotype 148.61 (7.32 to 10.12)11.04 (9.44 to 12.90)
Serotype 18C5.58 (4.89 to 6.36)8.46 (7.25 to 9.88)
Serotype 19A5.71 (4.91 to 6.64)7.05 (6.04 to 8.24)
Serotype 19F7.79 (6.73 to 9.01)9.30 (7.99 to 10.83)
Serotype 23F6.06 (5.16 to 7.12)9.81 (8.10 to 11.88)
Serotype 83.12 (2.78 to 3.49)0.05 (0.04 to 0.06)
Serotype 10A9.93 (8.58 to 11.50)0.03 (0.03 to 0.04)
Serotype 11A5.70 (4.96 to 6.54)0.01 (0.01 to 0.02)
Serotype 12F1.92 (1.68 to 2.20)0.02 (0.02 to 0.03)
Serotype 15B18.45 (16.43 to 20.72)0.04 (0.04 to 0.05)
Serotype 22F14.68 (12.62 to 17.08)0.01 (0.01 to 0.01)
Serotype 33F4.70 (4.20 to 5.27)0.05 (0.04 to 0.05)

Adverse events

Collected over Local reactions and Systemic events: within 7 days after each vaccination (systematic assessment), Non serious AEs: Vaccination 1 to 1 month after Vaccination 3 (up to 5 months) and Vaccination 4 to 1 month after Vaccination 4, SAEs: up to 16 months after Vaccination 1. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20vPnC0/231 (0%)12/231 (5.2%)225/231 (97.4%)
13vPnC0/227 (0%)5/227 (2.2%)224/227 (98.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
Event20vPnC13vPnC
GastroenteritisInfections and infestations1/2311/227
Parainfluenzae virus infectionInfections and infestations0/2311/227
PneumoniaInfections and infestations0/2311/227
Respiratory syncytial virus infectionInfections and infestations0/2311/227
Seizure like phenomenaNervous system disorders0/2311/227
AnaemiaBlood and lymphatic system disorders1/2310/227
BronchiolitisInfections and infestations1/2310/227
Bronchitis viralInfections and infestations1/2310/227
Croup infectiousInfections and infestations1/2310/227
Meningitis viralInfections and infestations1/2310/227
Most frequent other events
Showing 10 of 55
Most frequent other events
Event20vPnC13vPnC
Irritability (IRRITABILITY)Psychiatric disorders214/231206/227
Hypersomnia (INCREASED SLEEP)Nervous system disorders188/231189/227
Injection site pain (PAIN)General disorders163/231167/227
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders134/231136/227
Injection site erythema (REDNESS)General disorders112/231120/227
Pyrexia (FEVER)General disorders90/23190/227
Injection site swelling (SWELLING)General disorders76/23181/227
Upper respiratory tract infectionInfections and infestations40/23144/227
Otitis mediaInfections and infestations25/23121/227
TeethingGastrointestinal disorders10/23116/227

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(days)20vPnC13vPnCTotal
Mean64.5 ± 8.0764.5 ± 6.6864.5 ± 7.40
Sex: Female, Male
Sex: Female, Male(Participants)20vPnC13vPnCTotal
Female112115227
Male120113233
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20vPnC13vPnCTotal
Hispanic or Latino414081
Not Hispanic or Latino191188379
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20vPnC13vPnCTotal
American Indian or Alaska Native437
Asian9514
Native Hawaiian or Other Pacific Islander134
Black or African American352964
White161171332
More than one race221537
Unknown or Not Reported022
08

Study locations

39 sites
  • Northwest Arkansas Pediatrics
    Fayetteville, Arkansas 72703, United States
  • Premier Health Research Center, LLC
    Downey, California 90240, United States
  • St. Joseph Heritage Healthcare
    Huntington Beach, California 92648, United States
  • Kaiser Permanente Oakland
    Oakland, California 94611, United States
  • Orange County Research Institute
    Ontario, California 91762, United States
  • Kaiser Permanente South Sacramento
    Sacramento, California 95823, United States
  • Kaiser Permanente San Jose
    San Jose, California 95119, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • ACC Pediatric Research
    Haughton, Louisiana 71037, United States
  • MedPharmics, LLC
    Metairie, Louisiana 70006, United States
  • LSUHSC Shreveport
    Shreveport, Louisiana 71103, United States
  • University Health Shreveport
    Shreveport, Louisiana 71103, United States
  • Children's Physicians, Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • Child Health Care Associates
    East Syracuse, New York 13057, United States
  • Blue Ridge Pediatric and Adolescent Medicine, Inc.
    Boone, North Carolina 28607, United States
  • Capitol Pediatrics & Adolescent Center PLLC
    Raleigh, North Carolina 27609, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45206, United States
  • Cincinnati Children's Medical Center
    Cincinnati, Ohio 45206, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45225, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Pediatric Associates of Mt. Carmel, Inc.
    Cincinnati, Ohio 45245, United States
  • Ohio Pediatric Research Association, Inc.
    Dayton, Ohio 45414, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Oklahoma State University - Center for Health Sciences
    Tulsa, Oklahoma 74127, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • CCP - Kid's Way
    Hermitage, Pennsylvania 16148, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Coastal Pediatric Associates
    Charleston, South Carolina 29414, United States
  • Coastal Pediatric Research
    Charleston, South Carolina 29414, United States
  • Palmetto Pediatrics, PA
    North Charleston, South Carolina 29406-9170, United States
  • University of Texas Medical Branch
    Galveston, Texas 77555-1115, United States
  • Tekton Research, Inc.
    San Antonio, Texas 78240, United States
  • Wee Care Pediatrics
    Layton, Utah 84041, United States
  • Wasatch Pediatrics, Cottonwood Office
    Murray, Utah 84107, United States
  • Wee Care Pediatrics
    Roy, Utah 84067, United States
  • CopperView Medical Center
    South Jordan, Utah 84095, United States
  • Wee Care Pediatrics
    Syracuse, Utah 84075, United States
  • Pediatric Associates of Charlottesville, PLC
    Charlottesville, Virginia 22902, United States
  • Pediatric Research of Charlottesville, LLC
    Charlottesville, Virginia 22902, United States
09

References and documents

Publications

  • Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J, Peng Y, Giardina PC, Jansen KU, Gruber WC, Scott DA, Watson W. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021 Oct 1;40(10):944-951. doi: 10.1097/INF.0000000000003277. PubMed 34525007 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Feb 2020, 21 months.

Results were first posted in Mar 2021, 1 year after primary completion.

Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
Apr 30, 2018
StartActual
Apr 16, 2018
Primary completionActual
Feb 11, 2020
CompletionActual
Feb 11, 2020
Results first posted
Mar 2, 2021
Last update
Mar 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03512288
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 30, 2018
Start date
Apr 16, 2018
Primary completion
Feb 11, 2020
Completion
Feb 11, 2020
Results posted
Mar 2, 2021
Last update
Mar 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal Conjugate Vaccine

Start the discussion